Comparing the Two Common GLP-1 Receptor Antagonists, Ozempic and Wegovy: Drugs in the GLP-1 receptor agonist class help control blood sugar levels and are used to treat type 2 diabetes and weight loss.
Ozempic and Wegovy are two of the most widely used medications in this category. Both medications are FDA-approved for use in the treatment of type 2 diabetes because they have been proven to be successful in regulating blood sugar levels. However, there are certain distinctions between these two medications that merit thought.Semaglutide, an injectable medication called Ozempic, is administered subcutaneously once per week. It functions by boosting insulin secretion and reducing hepatic glucose synthesis. Additionally, it slows down digestion, which aids in regulating blood sugar levels following meals.
Metformin, sulfonylureas, and thiazolidinediones are among the other diabetes drugs that are frequently taken with ozempic.Wegovy is an intramuscular, once-weekly medication that comes in doses of semaglutide 2.4 mg and 3.0 mg. By boosting the release of insulin and reducing the synthesis of glucose in the liver, it functions similarly to Ozempic. Wegovy has been proven to be more successful in regulating blood sugar levels despite having a larger dose of semaglutide than Ozempic. Additionally, metformin, sulfonylureas, and thiazolidinediones are frequently used with wegovy for treating diabetes.When contrasting Ozempic with Wegovy, it's critical to take each medication's potential adverse effects into account. Both medicines have the potential to produce these side effects. Additionally, especially when taken in conjunction with other diabetes drugs, they may result in low blood sugar levels. Weight loss, a decrease in appetite, and injection site responses are some other Ozempic and Wegovy side effects.
References:
Drucker, D. J. (2017). The biology of incretin hormones. Cell Metabolism, 25(6), 975-990. https://www.cell.com/cell-metabolism/fulltext/S1550-4131(17)30236-X
Buse, J. B., & Nauck, M. A. (2017). Incretin-based therapies. Diabetes Care, 40(Suppl 2), S123-S130. https://care.diabetesjournals.org/content/40/Supplement_2/S123.long
Garber, A. J., & Grunberger, G. (2018). GLP-1 receptor agonists for type 2 diabetes mellitus. The Lancet Diabetes & Endocrinology, 6(2), 119-128. https://www.thelancet.com/journals/landia/article/PIIS2213-8587(17)30371-0/fulltext
Woerle, H. J., & Broedl, U. C. (2017). GLP-1 receptor agonists: an overview of their clinical use. Diabetes, Obesity and Metabolism, 19(Suppl 1), 3-15. https://onlinelibrary.wiley.com/doi/full/10.1111/dom.13005
